retatrutide clinical trial information Reta data & dosing โ a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health โ targeting GLP-1, GIP ๐๐ฅ Retatrutide: The Most Powerful
Description
Semaglutide 2.4 mg had a similar safety profile to semaglutide 1.0 mg and placebo
Fill, Pharm.D., MBA Last update: February 22, 2026 Est

We produced a once-weekly GLP-1 launched in 2014 called Trulicity

Bydureon BCise (exenatide extended-release) injection, for subcutaneous use: prescribing information

By decreasing glucagon release, these agonists support the body in maintaining more consistent blood sugar levels, which not only aids in weight loss but also provides overall metabolic benefits
There is substantial evidence that weight loss improves nearly all components of the lipid profile with sustained benefits for weight loss maintenance [23, 24]